Financial terms of the agreement were not disclosed.
"We believe ImClone Systems' decision to work with Neurome is an important validation of our discovery stage capabilities and proprietary technologies," said Floyd Bloom, chairman and founding CEO of Neurome.
In August, Neurome announced that it plans to buy all the assets owned by Digital Gene Technologies, including its gene-expression assays and gene-expression-analysis platform called TOGA (see story on Aug. 11).